Adopting a new stance on immunotherapy for uveal melanoma
Mené sur 21 patients atteints d'un mélanome de l'uvée, cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse objective, d'une immunothérapie adoptive par transfert de lymphocytes T autologues infiltrant les tumeurs
In The Lancet Oncology, Smita Chandran and colleagues report an unplanned interim analysis from a single-centre phase 2 clinical study of adoptive transfer of tumour-infiltrating lymphocytes (TILs) in patients with metastatic uveal melanoma.1 Unlike cutaneous melanoma, uveal melanoma has been relatively resistant to clinically approved immunotherapeutic agents. Anti-CTLA-4 blockade has achieved minimal efficacy in patients with advanced uveal melanoma, with only 0–7% of patients achieving a response, and no appreciable effects on overall survival in prospective studies of ipilimumab or tremelimumab.
The Lancet Oncology , commentaire, 2016